Latest Regulatory News

PTR Minerals reports exceptional heavy mineral assay results from 47 drill holes at its Rosewood Titanium Project, confirming thick, high-grade mineralisation and advancing metallurgical testing ahead of a maiden resource estimate due in Q2 2026.

Viking Mines has secured a comprehensive historical dataset for its Linka tungsten project in Nevada, significantly cutting exploration time and costs. This strategic acquisition lays the groundwork for rapid 3D geological modelling and targeted drilling.

Enova Mining has completed over 65% of its diamond drilling program at the East Salinas rare earth project in Brazil, with initial assay results expected by early February. The drilling targets high-grade rare earth mineralisation across multiple prospects, aiming to confirm continuity and support resource development.

Memphasys Limited has achieved its first material revenues following CE Mark approval for its Felix™ System, activating multi-year contracts across Europe, the Middle East, and Asia. The company is now transitioning from regulatory preparation to global commercial rollout with a focus on recurring revenues.

Osteopore Limited has inked a three-year exclusive distribution agreement with MontsMed to introduce its advanced orthopaedic trauma reconstruction products into Hong Kong, positioning itself strategically within the Greater Bay Area.

Peninsula Energy reports strong progress in ramping up uranium production at its Lance Project in Wyoming, with acidification exceeding expectations and key infrastructure developments on track. Supportive US government policies further enhance the company’s strategic outlook.

Gold Mountain Limited has agreed to sell its Papua New Guinea exploration licences for $2 million, redirecting funds to advance its promising Brazilian projects and strengthen working capital.

RPMGlobal has secured a crucial Foreign Investment Review Board approval for its proposed acquisition by Caterpillar, marking a significant step forward in the takeover process.

LTR Pharma has initiated dosing in its Phase II clinical trial for SPONTAN, a rapid-acting intranasal spray targeting erectile dysfunction, marking a key step toward FDA approval and commercial expansion.

1414 Degrees updates on the administration of its joint venture partner Vast Solar Aurora, exploring acquisition options while progressing key renewable projects. The company also advances its October 2025 placement with shareholder-approved options now moving towards ASX quotation.

Generation Development Group (ASX, GDG) has reported a robust December quarter, with Funds Under Management surging across its core divisions, driven by strategic partnerships and acquisitions.

Entropy Neurodynamics reports encouraging early clinical results from the first patient treated with TRP-8803, an IV-infused psilocin therapy for Binge Eating Disorder, showing improvements across multiple symptom areas.